Research Article
Serum Legumain Is Associated with Peripheral Artery Disease in Patients with Type 2 Diabetes
Table 1
Comparison of clinical characteristics between patients with and without PAD.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abbreviation: PAD: peripheral artery disease; WC: waist circumference; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; DR: diabetic retinopathy; DPN: diabetic peripheral neuropathy; DN: diabetic nephropathy; NAFLD: nonalcoholic fatty liver disease; FBG: fasting blood glucose; 2hPBG: 2 hours postprandial blood glucose; HbA1c: glycosylated hemoglobin; HOMA-IR: homeostatic model assessment-insulin resistance; TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; eGFR: estimated glomerular filtration rate; UA: uric acid; hs-CRP: hypersensitive C-reactive protein; HCY: homocysteine; OADs: oral antidiabetic drugs; ACEI/ARB: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CCB: calcium channel blocker. |